On this page
What each program costs in Alabama
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 6 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 7 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 10 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 12 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 13 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 14 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 15 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Getting a GLP-1 online in Alabama
A September 2023 statement from the Alabama State Board of Medical Examiners says these medicines should be prescribed only in direct consultation with a licensed professional, and relays the Board of Pharmacy's ban on compounding with semaglutide salts or non-pharmaceutical-grade ingredients.
Alabama State Board of Medical Examiners
The Board of Medical Examiners' September 2023 statement says GLP-1 medicines should be prescribed only in direct consultation with, and under the supervision of, a licensed professional.
“Consumers should be reminded that these medicines are legitimately available by prescription only, and should only be prescribed in direct consultation with, and under the supervision of, a licensed healthcare professional.”
https://www.albme.gov/uploads/pdfs/Semaglutide.pdf · read Oct 29, 2026
Alabama State Board of Medical Examiners
The same statement relays the Alabama Board of Pharmacy's notice that compounding with semaglutide salts or non-pharmaceutical-grade ingredients is prohibited.
“The Alabama Board of Pharmacy has notified all licensed pharmacists and pharmacies that even when compounding of a semaglutide drug product is allowable under the Food, Drug, & Cosmetic Act, the use of semaglutide salts, the use of any non-pharmaceutical grade active pharmaceutical ingredient (API), or one not produced by an FDA-registered establishment, is prohibited.”
https://www.albme.gov/uploads/pdfs/Semaglutide.pdf · read Oct 29, 2026
Alabama State Board of Medical Examiners
It also warns about online programs that prescribe after minimal evaluation.
“Some of these internet programs conduct minimal medical evaluations, and many sell unapproved compounded versions of the drugs, or even counterfeit drugs.”
https://www.albme.gov/uploads/pdfs/Semaglutide.pdf · read Oct 29, 2026
Does Alabama Medicaid cover GLP-1s for weight loss?
Not covered for weight loss
Alabama Medicaid's October 2026 drug list says Wegovy is non-covered for weight reduction and Zepbound is non-covered for weight reduction without sleep apnea. Read from state documents Nov 6, 2026.
What Alabama Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Alabama Medicaid Agency.
WegovyNo
Prior authorization for heart risk with established cardiovascular disease, or for MASH.
“Wegovy is non-covered for weight reduction.”
Acentra Health for Alabama Medicaid Agency · Effective Oct 1, 2026 · read Nov 6, 2026
“Wegovy is available via PA for its cardiovascular and metabolic”
Acentra Health for Alabama Medicaid Agency · Effective Oct 1, 2026 · read Nov 6, 2026
ZepboundNo
Preferred with clinical criteria for moderate to severe sleep apnea with obesity (BMI 30 or higher), age 18 or older, no diabetes.
“Zepbound is non-covered for weight reduction without OSA.”
Acentra Health for Alabama Medicaid Agency · Effective Oct 1, 2026 · read Nov 6, 2026
“For OSA indications for incretin mimetics, patient must be ≥18 years of age with moderate to severe obstructive sleep apnea”
Alabama Medicaid Agency · Effective Jul 1, 2026 · read Nov 6, 2026
OzempicUnclear
The 7/1/2026 criteria say incretin mimetics must meet criteria including FDA approved indications, and the Administrative Code excludes agents used for weight loss except those the agency specifies. Neither names Ozempic or Mounjaro for weight loss, and PDL listing does not settle it.
MounjaroUnclear
The 7/1/2026 criteria say incretin mimetics must meet criteria including FDA approved indications, and the Administrative Code excludes agents used for weight loss except those the agency specifies. Neither names Ozempic or Mounjaro for weight loss, and PDL listing does not settle it.
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Alabama Medicaid Agency documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
- Jul 1, 2026 · Policy changeAdded Wegovy to the preferred drug list with clinical criteria, for non-weight uses.
“PDL Additions StarjemzaCC TIMs/Biologics/DMARDs WegovyCC Incretin Mimetics”
Alabama Medicaid Agency · Effective Jul 1, 2026 · read Nov 6, 2026
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
1,471 prescriptions
Ozempic and Mounjaro, 2025
51,728 prescriptions
Neighbours covering weight loss
2 of 4
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Alabama Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Alabama Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Alabama Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Alabama Medicaid pay for?
71,772 GLP-1 prescriptions in 2025, 29th of the 50 states and DC, with $70.1 million reimbursed before rebates. Counting the share other payers covered, $72.3 million.
Prescriptions, 2025
71,772
29th of 51
Medicaid paid
$70.1M
29th of 51, before rebates
Per prescription
$977
$1,051 nationally
Weight-loss brands
2.0%
33rd highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Alabama is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 2.0% of Alabama Medicaid's GLP-1 prescriptions in 2025 (1,471). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Ozempic was Alabama Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Ozempic | 32,967 | 46% | $31.7 million | $960 |
| Mounjaro | 18,761 | 26% | $19.4 million | $1,035 |
| Trulicity | 15,261 | 21% | $14.5 million | $953 |
| Rybelsus | 2,407 | 3.4% | $2.3 million | $962 |
| Zepboundapproved for weight management | 1,043 | 1.5% | $1.1 million | $1,061 |
| Liraglutide (generic) | 720 | 1.0% | $372,741 | $518 |
| Wegovyapproved for weight management | 428 | 0.6% | $568,432 | $1,328 |
| Victoza | 156 | 0.2% | $90,797 | $582 |
| Bydureon | 29 | 0.0% | $24,744 | $853 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in Alabama?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 2 in Alabama. The register does not say which, if any, supplies a program on this page.
- Eagle Pharma, Birmingham. Registered since Jun 16, 2015; last FDA inspection Sep 29, 2026.
- F.H. Investments, Inc., Birmingham. Registered since May 13, 2025; last FDA inspection Dec 19, 2025.
On Medicare in Alabama?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Alabama and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
2 of the 4 states next to Alabama cover GLP-1s for weight loss through Medicaid: Mississippi and Tennessee. None has a lower cash floor than Alabama's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Alabama | Not covered | 15 | $39/mo |
| Florida | Not covered | 19 | $39/moWellmedr |
| Georgia | Not covered | 18 | $39/moWellmedr |
| Mississippi | Covered | 15 | $39/moWellmedr |
| Tennessee | Covered | 18 | $39/moWellmedr |


















